Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is an open, multicenter phase II trial of therapy with a combination of cetuximab, and
irinotecan every second week combined with a daily dose of everolimus to patients with
metastatic colorectal cancer with Kirsten rat sarcoma viral oncogene (KRAS) mutation or to
patients resistent to cetuximab and irinotecan therapy for metastatic colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Herlev Hospital
Collaborators:
Aalborg Universitetshospital Aalborg University Hospital Odense University Hospital